ABSTRACT -Gene therapy may be the next major advance for treatment of many diseases, and severe haemophilia (an inherited deficiency of coagulation factor VIII or IX) is a useful model. Progress in gene therapy has been slowed down following fatal multi-organ failure during an adenovirus vector trial for ornithine-transcarbamylase deficiency and two episodes of leukaemia in a retroviral vector trial for severe combined immunodeficiency trial. A small number of early haemophilia clinical trials are in progress or reported. This paper considers ethical and statutory issues related to gene therapy for severe haemophilia within the UK and how these can be addressed through a well-established national network of haemophilia centres. It is likely that these issues will be relevant to clinicians considering gene therapy for other diseases.
Gene therapy may be the next major advance for treatment of many diseases, and severe haemophilia (an inherited deficiency of coagulation factor VIII or IX) is recognised as a useful model. 1, 2 The UK is an attractive country for haemophilia gene therapy trials because of national coordination through the UK Haemophilia Centre Doctors' Organisation (UKHCDO), centres experienced in performing clinical trials and the robust regulatory system. The UKHCDO wishes to collaborate with regulatory agencies to facilitate gene therapy in the UK and ensure the highest possible safety mechanisms.
Clinical and scientific basis
Severe haemophilia is ideal for somatic gene therapy for clinical and scientific reasons. Although complications are avoidable with prophylactic treatment, this is invasive and has significant morbidity in young children. Coagulation factor replacement is expensive and supply uncertain. Previously, plasmaderived therapy resulted in transmission of HIV and hepatitis and patients now expect state-of-the-art treatment. World-wide, most haemophiliacs have no effective therapy.
Haemophilia is caused by a single gene defect treatable by single gene addition. There is a wide therapeutic range of clotting factor levels; tissuespecific production of clotting factor is probably unimportant, and a small increase from baseline levels leads to a measurable and clinically significant benefit. Patients and families are well informed and likely to volunteer for studies. Those who treat haemophilia are experienced in performing clinical trials to high standards and follow-up will be good.
These advantages must be balanced against concerns about serious adverse events in recent trials. 3, 4 Haemophilia is no longer a life-threatening disease and replacement therapy, if available, is safe and efficacious. Gene therapy may induce inhibitor development (allo-antibodies that inhibit FVIII/IX) and the antigenic stimulus may not be easily removed. Gene therapy in patients infected with HIV and hepatitis may interfere with the course of these diseases.
Scientific, safety, research and ethical issues in human gene therapy trials in haemophilia
Gene therapy may be viewed as qualitatively different from other treatments, but from a broader perspective it is a natural progression in the application of biomedical science to medicine. Progress in gene therapy, however, has been slowed following fatal multi-organ failure during an adenovirus vector trial for ornithine-transcarbamylase deficiency, 3 and two episodes of leukaemia in a retroviral vector trial for severe combined immunodeficiency trial. 4 Overzealous reporting and media interest in early studies in gene therapy have obscured their exploratory nature and heightened expectations. Research in gene therapy for haemophilia is now catching up. Five clinical trials involving 25 patients are in progress or completed with early reports available. 1, 2, 5 Dermal fibroblasts transfected by a FVIII vector using electroporation and reimplanted in the omentum led to a transient small FVIII increment. 6 An adeno-associated viral (AAV) FIX vector given intramuscularly led to gene transfer confirmed by biopsy. 7 An AAV vector expressing a FIX minigene has been administered via the hepatic artery; vector DNA was transiently detected in semen. 8 A retroviral vector expressing B-domain deleted factor VIII given intravenously in severe haemophilia A led to some patients having measurable FVIII levels and decreased bleeding frequency. 9 A patient treated with a gutless adenovirus vector had a FVIII level rise above 1%. The study was suspended transiently following hepatotoxicity and thrombocytopenia. Expansion of pilot studies or modified protocols are inevitable but safety issues must be paramount.
Scientific and safety issues
The following questions need to be answered: 9 Should patients be allowed to undergo multiple protocols sequentially?
Ethical issues
Adults can give informed consent and should be the initial subjects. It is likely, however, that children will be enrolled as they will be free of HIV and HCV infection and benefit more from avoiding intravenous prophylactic infusions 3-4 times a week. Even given the provisions of the Children's Act 1989 in relation to consent (ie assent being obtained from the child and consent by a parent on behalf of the child), is it ethical to enrol children when long-term side effects are unknown and long-term followup is required?
Regulation of gene therapy in the UK
Regulation of human gene therapy research is subject to additional regulation compared with other trials. Central to this process is the Gene Therapy Advisory Committee (GTAC).
Gene Therapy Advisory Committee
GTAC was established to oversee gene therapy research in the UK following the recommendations of the Clothier Committee on the ethics of gene therapy. 10 GTAC's terms of reference are to: advise on proposals for gene therapy research on humans on ethical grounds, taking account of the scientific merits of the proposals and the potential benefits and risks work with other agencies including local research ethics committees, the Medicines Control Agency (MCA), the Health and Safety Executive and the Department of the Environment provide advice to health ministers on gene therapy research. GTAC stipulates that all gene therapy research and recruitment into trials must take place under strict rules set out by and only after review of clinical protocols by GTAC.
Local Research Ethics Committees (LRECs) and GTAC
Gene therapy research must comply with standard LREC review and be seen to be conducted in a way that is beyond reproach. GTAC complements this by undertaking an authoritative and enabling review of protocols to establish whether a proposal meets accepted ethical criteria. 
Key Points
Severe haemophilia is a suitable disorder for somatic gene therapy because a small increase in coagulation factor level causes a substantial decrease in the frequency of bleeding episodes Gene therapy trials in haemophilia are likely to be introduced in the UK soon because of the national coordination of care, the experience of haemophilia centres in performing clinical studies to a high standard, and the existence of robust regulatory systems 
UK national haemophilia gene therapy register
Gene therapy protocols used in the UK for the treatment of haemophilia will be registered with GTAC, but UKHCDO should also be aware of their existence and each trial should be registered with the organisation. Patients who have entered a gene therapy trial should have this information recorded on the national haemophilia database (as with any conventional haemostatic treatment) to enhance safety, improve adverse reporting and ensure long-term surveillance of subjects. This will be important if patients are exposed to multiple gene therapy protocols, move area or unexpected complications develop from different protocols after many years.
Conclusions
Haemophilia offers an ideal model for the development of gene therapy, but it is recognised that, from a commercial point of view, disorders such as cancer and cardiovascular disease will be more attractive. Once developed, gene therapy protocols should be applicable to most, if not all, people with haemophilia including those with hepatitis and HIV. It is important that haemophilia is not used simply as a model for gene therapy, but experience gained from such studies will potentially benefit patients with a wide range of other conditions.
